Grace Therapeutics, INC

Grace Therapeutics, Inc. announced the results of its Annual Meeting of Stockholders, confirming the election of directors and approval of key proposals.

Grace Therapeutics announced its second quarter 2026 financial results, reporting a net loss of $15.8 million and providing an update on the ongoing efforts to resubmit its New Drug Application for GTx-104.

Grace Therapeutics announced receipt of FDA meeting minutes regarding GTx-104, outlining a path for NDA resubmission with a dual-source manufacturing strategy.

Grace Therapeutics, Inc. has updated its corporate presentation, detailing progress on its lead drug candidate GTx-104 for aneurysmal subarachnoid hemorrhage (aSAH) and providing an update on its other programs.

Grace Therapeutics announced its fiscal year-end financial results for 2026, reporting a reduced net loss and providing an update on its GTx-104 New Drug Application following a Complete Response Letter from the FDA.

Grace Therapeutics announces the departure of VP of Clinical Operations Carrie DAndrea, who will transition to a consulting role.

Grace Therapeutics Inc. reported its Q2 2026 financial results, highlighting a net loss of $15.79 million and a significant impairment charge, while continuing efforts to address FDA feedback on its lead drug candidate, GTx-104.

Grace Therapeutics reports significant progress for its lead drug candidate GTx-104 with FDA NDA acceptance and a PDUFA target date set for April 23, 2026, alongside reduced net losses.

Grace Therapeutics, Inc. filed an amended quarterly report (10-Q/A) to correct the reported number of outstanding common shares as of November 13, 2025.

Grace Therapeutics reported reduced net losses and cash burn, with its lead drug candidate GTx-104 progressing towards FDA approval with a PDUFA date set for April 23, 2026.

Grace Therapeutics, Inc. reported submitting its New Drug Application for lead candidate GTx-104 to the FDA, following positive Phase 3 trial results for aneurysmal subarachnoid hemorrhage.

Grace Therapeutics files an amendment to its Form 10-Q to correct the number of outstanding shares of common stock as of December 31, 2024.

Grace Therapeutics reported a net loss for the fiscal year ended March 31, 2026, and received a Complete Response Letter from the FDA for its GTx-104 drug candidate.

Grace Therapeutics, Inc. announced positive Phase 3 clinical trial results for its lead drug candidate, GTx-104, and plans for an FDA New Drug Application submission in the first half of calendar year 2025, despite reporting continued operating losses and a need for additional capital.

Acasti Pharma prioritizes its lead drug candidate, GTX-104, for aneurysmal subarachnoid hemorrhage, while reporting a reduced net loss for fiscal year 2024.

Opaleye Management Inc. reported changes in beneficial ownership of Grace Therapeutics, Inc. common stock on September 21, 2026.

Edward Neugeboren, a Director of Grace Therapeutics, Inc., received 12,200 shares of common stock on September 17, 2026.

A Brian Davis, a Director of Grace Therapeutics, Inc., reported multiple transactions in common stock on September 17, 2026.

George Kottayil, a Director of Grace Therapeutics, Inc., received 12,200 shares of common stock on September 17, 2026.

Prashant Kohli, Chief Executive Officer and a Director of Grace Therapeutics, Inc., purchased 100,000 shares of common stock on September 9, 2026 for $2.14 per share.

Opaleye Management Inc. reported changes in beneficial ownership of Grace Therapeutics, Inc. common stock on August 14, 2026.

Grace Therapeutics, Inc. has filed definitive additional proxy materials with the SEC.

Grace Therapeutics, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on September 12, 2025, seeking approval for director nominees, executive compensation, and auditor ratification.

Acasti Pharma encourages shareholders to vote on key proposals, including director elections, auditor appointment, executive compensation, and corporate restructuring, before the upcoming Annual and Special Meeting on September 30, 2024.

Acasti Pharma Inc. has filed a definitive proxy statement with the U.S. Securities and Exchange Commission.

ADAR1 Capital Management, along with affiliates, has reported beneficial ownership of 9.9% of Grace Therapeutics, Inc. common stock, primarily through warrants.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 6.75% of Grace Therapeutics, Inc. common stock as of June 30, 2026.

ADAR1 Capital Management and Daniel Schneeberger have reported a 9.9% beneficial ownership stake in Grace Therapeutics, Inc. through common stock and warrants.

AIGH Capital Management and affiliated entities report a 4.9% stake in Grace Therapeutics, Inc., primarily through exercisable warrants.

AIGH Capital Management LLC and Orin Hirschman have disclosed a 5.9% beneficial ownership stake in Grace Therapeutics, Inc., holding 907,217 common shares.

ADAR1 Capital Management, ADAR1 Capital Management GP, and Daniel Schneeberger have reported a 9.9% beneficial ownership stake in Grace Therapeutics, Inc. as of September 30, 2025.